Agents against common colds, SARS and other coronaviral diseases
Human coronaviruses (HcoV) are the major cause of diseases of the upper respiratory tract in humans. Apart from the common cold these include e.g. the life-threatening severe acute respiratory syndrome (SARS), that, originating in China, has appeared in other parts of the world with a mortality rate of 15%. A key enzyme for the replication cycle of the coronavirus is the HcoV proteinase Mpro. The functional relevance of Mpro makes it an attractive target for the development of drugs against SARS and other coronaviral diseases.
The present invention relates to a group of anticoronaviral agents whose functional mechanism is based on the specific blockade of the substrate binding site of HCoV Mpro. In vitro test systems have shown the substances according to the invention to be highly effective against several coronaviruses.
Further Information: PDF
Patent- und Verwertungsagentur für die Wissenschaftlichen Einrichtungen in Schleswig-Holstein GmbH (PVA SH)
Phone: +49 (0)431/8009937
Contact
Dr. Alexandra Baumgartner
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Silicon Carbide Innovation Alliance to drive industrial-scale semiconductor work
Known for its ability to withstand extreme environments and high voltages, silicon carbide (SiC) is a semiconducting material made up of silicon and carbon atoms arranged into crystals that is…
New SPECT/CT technique shows impressive biomarker identification
…offers increased access for prostate cancer patients. A novel SPECT/CT acquisition method can accurately detect radiopharmaceutical biodistribution in a convenient manner for prostate cancer patients, opening the door for more…
How 3D printers can give robots a soft touch
Soft skin coverings and touch sensors have emerged as a promising feature for robots that are both safer and more intuitive for human interaction, but they are expensive and difficult…
